Recent Work
-
Paying for Cancer Drugs That Prove Their Benefit
The United States pays prices for brand-name drugs that are estimated to be 256% higher than other wealthy nations. As the accelerated approval of aducanumab for Alzheimer disease shows, high prices (announced price for aducanumab is $56 000 per year) extend to drugs that are promising but have not been shown by randomized clinical trials to provide long-term clinical benefits.
Categorized in